ImmuSAFE™ COVID+ Biochip

Product Specifications

Product Name	ImmuSAFE™ COVID+ Biochip Test
Product Name	ImmuSAFE™ COVID+ Biochip Test
Platform	Sengenics’ KREX™ proprietary surface which preserves protein folding and inhibits binding of non-specific proteins
Content	Multiple domains of SARS-CoV-2 Nucleocapsid and Spike proteins including full-length and numerous truncated versions
Number of Arrays	24 arrays per slide (24 samples per slide)
Sample Type	Human Serum/Plasma
Assay Type	Single-colour fluorescently-labelled antibody assay Dual-colour fluorescently-labelled antibody assay
System Compatibility	Any open-format microarray scanner (Example: Agilent, InnoScan, Genepix or Tecan Scanner)

Biochip Layout

Validation Data

Biochip Layout

Control Probes:

Positive control
1. Cy3-BSA
2. Cy5-BSA
3. IgA (positive control for total immunoglobulins detection)
4. IgG (positive control for IgG and total immunoglobulins detection)
5. IgM (positive control for IgM and total immunoglobulins detection)

Negative control
1. IgA (negative control for IgG and IgM detection)
2. IgG (negative control for IgM detection)
3. IgM (negative control for IgG detection)
4. Negative control probe for total immunoglobulins detection

Validation Data

ImmuSAFE is able to determine titre and position of antibodies.

Figure 1: Overall breadth of epitope coverage in all 50 cases. All positive samples showed antibody reactivity towards at least 1 domain and displayed diverse locality distribution. The numerical value in each red dot represents the number of total antigens with positive antibody reactivity.

ImmuSAFE data shows that antibody coverage and titre increases with age.

Figure 2: A positive correlation between increasing age of COVID-19 patients and higher Epitope Coverage scores (EPC) was observed. The figure on the bar plot represents the average number of antigens with positive immunoreactivity exhibited by each age group.